72 completed, 6 recruiting, 5 active not recruiting, 4 terminated. 47 Phase 3, 34 Phase 2, 11 Phase 1, 4 Not applicable, 3 Phase 4.
Follow Vehicle cream: new trials by email Literature Review of Vehicle cream trials Research Report on Vehicle cream
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Topical 2% Simvastatin for Xanthelasma Palpebrarum Topical Simvastatin 2% Cream, Vehicle cream - Xanthelasma Palpebrarum | Phase 2 | Not yet recruiting | Klira Skin | 30 | 2026-08-01 | 2026-06-23 |
| Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-III) Total coumarin (TC) cream, Vehicle cream - Psoriasis Vulgaris, Topical Administration | Phase 3 | Recruiting | Psoriasis Research Institute of Guangzhou | 300 | 2026-02-01 | 2026-02-23 |
| Safety, Efficacy and Pharmacokinetic Characteristics of KR230109 Cream in Facial Acne Vulgaris KR230109 cream 0.025%, KR230109 cream 0.05%, Placebo - Acne Vulgaris | Phase 2 | Not yet recruiting | Jiangxi Kvvit Pharmaceutical Co., Ltd. | 180 | 2026-01-10 | 2026-01-15 |
| A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis Tapinarof cream, 1%, Vehicle Cream - Atopic Dermatitis | Phase 3 | Suspended | Organon and Co | 187 | 2025-12-29 | 2026-10-05 |
| A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo Ruxolitinib Cream, Vehicle Cream - NonSegmental Vitiligo | Phase 3 | Recruiting | Incyte Corporation | 250 | 2025-11-13 | 2026-10-09 |
| A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris Trifarotene, Vehicle Cream - Acne Vulgaris | Phase 3 | Active not recruiting | Galderma R&D | 561 | 2025-09-23 | 2026-08-24 |
| A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis Delgocitinib cream, Vehicle cream - Palmoplantar Pustulosis | Phase 2 | Recruiting | LEO Pharma | 135 | 2025-09-11 | 2026-10-01 |
| Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1) Ruxolitinib Cream, Vehicle Cream - Hidradenitis Suppurativa | Phase 3 | Active not recruiting | Incyte Corporation | 580 | 2025-06-23 | 2026-07-28 |
| A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis Ruxolitinib, Vehicle Cream - Atopic Dermatitis | Phase 3 | Active not recruiting | Incyte Corporation | 159 | 2025-06-17 | 2026-08-19 |
| Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2) Ruxolitinib Cream, Vehicle Cream - Hidradenitis Suppurativa | Phase 3 | Active not recruiting | Incyte Corporation | 573 | 2025-06-12 | 2026-07-08 |
| Antimicrobial Adjuvants to Revert the Imbalance of Skin Microbiota for Improved Outcomes of Complicated Cutaneous Leishmaniasis Treatment in Ethiopia Fusidic Acid, Vehicle cream - Leishmaniasis, Cutaneous | Phase 3 | Not yet recruiting | Institute of Tropical Medicine, Belgium | 180 | 2025-04-01 | 2024-11-19 |
| Randomised Controlled Trial of an Antioxidant and Sunscreen Combination Cream for Reducing DNA Damage in Human Skin Antioxidant + Sunscreen Cream, Placebo cream - Photoaging, Photodamage | Not applicable | Completed | Klira Skin | 52 | 2025-03-01 | 2025-12-24 |
| A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo Ruxolitinib Cream, Vehicle Cream - NonSegmental Vitiligo | Phase 3 | Recruiting | Incyte Corporation | 180 | 2025-01-24 | 2026-09-14 |
| Topical Anti-Androgens in Pilonidal Sinus Disease 1% Clascoterone, Vehicle Cream - Pilonidal Disease, Pilonidal Disease of Natal Cleft | Phase 2 | Recruiting | University of Pennsylvania | 75 | 2025-01-10 | 2026-02-27 |
| Efficacy and Safety of Roflumilast Cream in Subjects With Atopic Dermatitis Roflumilast Cream 0.15%, Vehicle cream - Atopic Dermatitis (AD) | Phase 3 | Completed | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 354 | 2024-11-21 | 2025-09-02 |
| Efficacy and Safety of Roflumilast Cream 0.3% in Subjects With Plaque Psoriasis: a Phase 3 Study Roflumilast Cream 0.3%, Vehicle cream - Plaque Psoriasis | Phase 3 | Completed | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 190 | 2024-11-14 | 2026-07-06 |
| Evaluate the Efficacy and Safety of Xianglei Tangzu Gao for the Treatment of Wagner Grade II Diabetic Foot Ulcers Xianglei Tangzu Gao, Vehicle Cream - Diabetic Foot Ulcer | Phase 2 / Phase 3 | Active not recruiting | Oneness Biotech Co., Ltd. | 120 | 2024-08-16 | 2026-06-12 |
| Efficacy and Safety of Clascoterone Cream 1% in Facial Acne Vulgaris Clascoterone, Vehicle cream - Acne Vulgaris | Phase 3 | Recruiting | Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. | 692 | 2024-05-20 | 2025-07-09 |
| A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis Ruxolitinib Cream, Vehicle Cream - Atopic Dermatitis | Phase 3 | Completed | Incyte Corporation | 241 | 2024-04-26 | 2026-10-15 |
| A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema Delgocitinib, Vehicle cream - Chronic Hand Eczema | Phase 3 | Completed | LEO Pharma | 362 | 2023-09-05 | 2025-09-25 |
Showing 20 of 96. Sign in to see all of them.
Dermatitis, Atopic (23) · Eczema (13) · Acne Vulgaris (12) · Psoriasis (9) · Skin Diseases (9) · Keratosis, Actinic (8) · Pruritus (7) · Dermatitis (3) · Hidradenitis Suppurativa (3) · Rosacea (3) · Neuralgia (2) · Prurigo (2) · Vitiligo (2) · Condylomata Acuminata (1) · Diabetic Foot (1)
Incyte Corporation (16) · Arcutis Biotherapeutics, Inc. (6) · Organon and Co (5) · Actavis Inc. (4) · GlaxoSmithKline (4) · Galderma R&D (3) · LEO Pharma (3) · AmDerma (2) · Bausch Health Americas, Inc. (2) · Cassiopea SpA (2) · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (2) · Haus Bioceuticals (2) · Klira Skin (2) · MEDA Pharma GmbH & Co. KG (2) · Oneness Biotech Co., Ltd. (2)
United States (67) · Canada (32) · Germany (14) · France (13) · Poland (12) · Italy (9) · Spain (8) · Bulgaria (7) · China (6) · Belgium (5) · United Kingdom (5) · Hungary (4) · Netherlands (4) · Dominican Republic (3) · Japan (3)
David Berk, MD (5) · Anya Loncaric (2) · Diana Villalobos (2) · Haq Nawaz, MD (2) · Helene Bertrand, MD, CM, CCFP (2) · Michael E. Kuligowski, MD, PhD, MBA (2) · Srinivas Sidgiddi, MD (2) · Victoria Butners (2) · Alexandra DJ Mancini, MSc (1)
PMID 40600584, PMID 37076998, PMID 38777187, PMID 32320027, PMID 33658996, PMID 33957195, PMID 33982267, PMID 34607697, PMID 36264430, PMID 36745367, PMID 37636253, PMID 37697121, PMID 38123875, PMID 38698175, PMID 39292443, PMID 39375281, PMID 39546129, PMID 39777610, PMID 39799945, PMID 40383273, PMID 40696240, PMID 41678112, PMID 25978942, PMID 32653055, PMID 32668113, PMID 34879448, PMID 36125472, PMID 36370336, PMID 36422852, PMID 36574595, PMID 37840766, PMID 38995504, PMID 39980188, PMID 40378883, PMID 41134450, PMID 41795905, PMID 42776548, PMID 42869214
2018 (2), 2004 (1), 2023 (1)